Which countries have approved eteplirsen so far?
Eteplirsen (EXONDYS 51) has regulatory approval in the United States for treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the dystrophin gene that is appropriate for exon 51 skipping [1]. The provided sources do not list additional national approvals beyond the U.S.
What is its approval status in the U.S.?
In the U.S., the FDA approved eteplirsen (EXONDYS 51) for DMD patients with a confirmed mutation amenable to exon 51 skipping [1].
Has eteplirsen been approved elsewhere in the world (e.g., Europe, Japan)?
The provided information does not specify regulatory approvals in Europe, Japan, or other countries. It only confirms U.S. approval [1].
Are there differences between regulatory approvals and market availability?
The sources provided confirm FDA approval [1], but they do not provide details on pricing, reimbursement, launch status, or whether authorization translated into broad market availability in other regions.
Where can approvals be verified if you need the exact latest status?
For the most reliable, country-specific status (especially if you’re tracking changes after FDA action), use the regulator’s approval database for each jurisdiction. In the U.S., the key reference is the FDA approval documentation for EXONDYS 51 [1].
What does “global approvals” mean for eteplirsen given the available data?
Based on the provided sources, “global regulatory approvals” can currently be supported only for the United States (FDA) [1]. No other countries’ approvals are mentioned.
Sources
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203513